TG Therapeutics agrees to purchase a global license to a Car T cell therapy program for autoimmune diseases
TG Therapeutics Inc.'s stock (TGTX) rallied 11% early Wednesday, after the biotech said it's entered an agreement with microcap Precision BioSciencies Inc. (DTIL) to acquire a worldwide license to that company's Azercabtagene Zapreleucel, or azer-cel, a CAR T cell therapy program for autoimmune diseases and other non-oncology indications. "Azer-cel is an allogeneic (off the shelf) CAR T program and the Company has near-term plans to evaluate the program in multiple autoimmune indications, with an investigational new drug (IND) filing targeted for mid-2024," TG Therapeutics said in a statement. Under the terms of the deal, Precision will be entitled to upfront and near-term payments valued at $17.5 million, comprised of an upfront payment of $7.5 million and the purchase of Precision common stock by TG Therapeutics at a 100% premium to the 30-day VWAP (volume weighted average price) prior to purchase. Precision will receive a further $2.5 million due within 12 months as an equity investment in its stock also at a 100% premium to the then VWAP priort to purchase. It will receive another $7.5 million split between cash and stock on those same terms on reaching certain clinical milestones. Precision will also be entitled to up to $288 million in payments based on reaching clinical, regulatory and commercial milestones, along with high-single-digit to low double-digit royalties on net sales. Precision's stock was down 1.9% premarket.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
01-10-24 0736ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst